Clinical Trial Update: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update for GB491 in combination with letrozole in HR-positive, HER2-negative advanced breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• GB491
• Letrozole (letrozole)

Snippet

Sponsor: Genor Biopharma Co., Ltd. | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING